Abstract:Background: The optimal biomarker to select suitable patients for immune checkpoint blockades (ICBs) therapy remains to be well established. The dynamic variations of molecular alterations during ICBs treatment need to be better understood. Here,we explored a novel biomarkerbased on T cell receptor (TCR) repertoire (TcR) and traced the variations during PD-L1 blockade delivery.Methods:Patients treated with anti-PD-L1 clinical trials were enrolled in this pilot study (n=21). Next-generation sequencing (NGS) was performed to assess molecular tumor burden index (mTBI) based on a 1021 gene panel, for genomic DNA from tumor tissue and cfDNA. Multiple PCR and NGS on the CDR3 region of TCR beta chain was used to reflect the distribution of T cell clones in TILs and peripheral CD8+PD1+ T cells. We applied gene altation data combined with each patient’s major histocompatibility complex (MHC) class I haplotype in a neoantigen prediction platform that evaluates binding affinities of somatic peptides to class I MHC, antigen processing, and self-similarity. Neoantigen peptides were synthesis and used to stimulate Peripheral blood mononuclear cell(PBMC)from the same patient. The expression of OX-40 and 4-1BB were anylisied by flow cytometry to determine activity change of stimulated T cells. Results: A number of T cell clones (1-24) in TILs were shared in peripheral CD8+PD1+ T cells. The total ratio of shared clones to top 100 clones in TILs ranged from 0.00% to 31.35%, while the mean ratio of each shared clone was 1.24% (0.00% to 3.18%). Patients responding to anti-PD-L1 therapy showed higher mean ratio of shared clonesthan non-responding ones (1.76% vs. 0.85%; P= 0.012), our further analysis showed the progression free survival (PFS) is also longer in patients with higher mean ratio of shared clones (P=0.022). Intriguingly, the ratio of shared clones to total CD8+PD1+ T cell clones of peripheral blood showed synchronized change consistent with mTBI and tumor burden. PBMC stimulated by neoantigen peptide expressed higher OX-40 and 4-1BB than control. Further TCR sequencing performed on stimulated T cells showed consistency with shared clone at baseline. Conclusion: The high mean ratio of shared clones in TILs is a potential and promising biomarker to predict the efficacy of ICBs therapy and reflect the target T lymphocytes variations during the treatment, which warrants the further validation in large cohort. Note: This abstract was not presented at the meeting. Citation Format: Jiefei Han, Zhijie Wang, Yuqi Wang, Si Chen, Hua Bai, Jianchun Duan, Jie Wang. The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3222.

Figure S5 from T Cells Expanded from PD-1<sup>+</sup> Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

Peripheral T cell expansion predicts tumour infiltration and clinical response

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Dynamics of Peripheral T Cell Clones During PD-1 Blockade in Non-Small Cell Lung Cancer.

Abstract 3222: the Sharing of T Cell Clones in Peripheral CD8+PD-1+ T Cells with TILs is a Novel Biomarker Predicting the Efficacy of Anti-Pd-l1 Therapy

Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

The Sharing of T Cell Clones in Peripheral CD8+PD-1+T Cells with TILs is a Novel Biomarker Predicting the Efficacy of Anti -PD-L1 Therapy

Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer

LAG-3 blockade reactivates the CD8 T cell expansion program to re-expand contracted clones in the tumor

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Peripheral CX3CR1+ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer

Adaptive Information Extraction from Structured Text Documents

Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Figure S5 from T Cells Expanded from PD-1&lt;sup&gt;+&lt;/sup&gt; Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes